

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number  
**WO 2004/016623 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 501/00**,  
A61K 31/546

**LUDESCHER, Johannes** [AT/AT]; Kleinsöhl 101,  
A-6252 Breitenbach (AT).

(21) International Application Number:  
PCT/EP2003/008944

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intel-  
lectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 12 August 2003 (12.08.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM,  
TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
1223/2002 13 August 2002 (13.08.2002) AT  
1588/2002 18 October 2002 (18.10.2002) AT

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **SANDOZ  
GMBH** [AT/AT]; Biochemiestrasse 10, A-6250 Kundl  
(AT).


Published:  
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KREMMINGER,  
Peter** [AT/AT]; Weitschön 86, 6250 Kundl (AT). **WOLF,  
Siegfried** [AT/AT]; Judenwiese 4a, 6230 Brixlegg (AT).

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: A CEFDINIR INTERMEDIATE



(57) Abstract: 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula (I), in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula (I) in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.